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ABSTRACT 
 
Background: Approximately one third of patients with epilepsy are refractory to medical 
treatment. Adverse effects associated with anti-epileptic drugs (AEDs) are considered to affect 
quality of life often more than the seizures themselves. Neuroimaging techniques, in particular 
magnetic resonance imaging (MRI), have proven instrumental in clinical decision making in 
relation to epilepsy surgery, but may also provide further insights into the mechanisms 
underlying treatment response and side effects associated with AEDs. 
Objective and Method: We searched PubMed and Ovid Medline databases for original 
articles and reviews published in the last two decades, which addressed the effects of AEDs on 
MRI and magnetic resonance spectroscopy (MRS) measures. 
Results: The majority of investigations implemented task-based fMRI, and probed the 
influence of widely used anti-epileptic drugs on tasks assessing language, executive functions 
and emotion recognition. Collectively, MRI is able to detect reproducible AED-related effects 
on regions and networks relevant to disease pathomechanisms, and so elucidates the anatomo-
functional substrates of cognitive side effects. MRS analyses shed light on the molecular 
correlates of AED action, and may provide indicators of treatment response.  
Conclusion: MRI and MRS have considerably improved our understanding of the effects of 
AEDs at a regional and network level, and provide biomarkers with potential to improve 
routine clinical decision making in epilepsy. 
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1. INTRODUCTION 
 
Epilepsy is characterized by the neurobiological, cognitive, psychological, and social 
consequences of this condition, which are confounded by treatment. . Refractoriness to 
pharmacological treatment, termed as ‘drug-resistance’, is estimated to occur in about 30% of 
patients with epilepsy (Sander, 2003; Kwan et al., 2010), despite significant advances in drug 
development over the last two decades, leading to more than twenty anti-epileptic drugs 
(AEDs). Moreover, AED-correlated adverse effects play a role in determining treatment 
failures, are associated with morbidity and mortality, and can considerably affect quality of life 
of people with epilepsy (Perucca and Gilliam, 2012). 
Neuroimaging, in particular magnetic resonance imaging (MRI), contribute to diagnosis and 
clinical management (Bernasconi et al., 2011; Duncan et al., 2016). Advanced MRI techniques 
prove useful in characterising functional and structural brain networks in vivo (Honey et al., 
2007; Sporns, 2012; Bernhardt et al., 2013; Caciagli et al., 2014), and provide objectively 
measurable traits, which exhibit validity as indicators of biological processes as well as high 
test-retest reliability, thus fulfilling the defining criteria of a biomarker (??? 2001; Koepp, 
2016). Given their ability to identify anatomo-functional markers of disease effects, MRI 
techniques have also been utilised to detect measurable responses to pharmacological 
interventions, with the aim to optimise medication choices at the individual level, and aid 
rationalisation of polytherapy strategies (van Veenendaal et al., 2015; Wandschneider and 
Koepp, 2016). In this context, functional MRI (fMRI) investigations shed light on regional and 
network-level dynamics, and may prove particularly sensitive in unveiling drug-related effects 
(Nathan et al., 2014; Beltramini et al., 2015). As well as identifying markers of treatment 
response and dose-response relationships, fMRI also conveys the possibility to address a 
variety of cognitive functions via specific tasksrelevant to epilepsy, which is accompanied by 
cognitive comorbidities. with AEDs often causing additional cognitive side effects (Ortinski 
and Meador, 2004; Hermann et al., 2008; Mula and Trimble, 2009).  
In this review, we will summarise the most recent studies investigating the effects of common 
AEDs on MRI parameters. We will focus first on pharmacological fMRI (phMRI) studies, 
though relevant insights from other, structural MRI and magnetic resonance spectroscopy 
(MRS) metrics will also be discussed. to probe the neurochemical underpinnings of AED 
effects in vivo.  
 
 2. MRI BIOMARKERS OF AED ACTION: AN OVERVIEW 
 
Ph-MRI study designs provide imaging correlates of AED effects. While structural MRI 
metrics evaluate the integrity of grey matter structures and of the interconnecting white matter 
tracts, fMRI conveys an indirect measure of neuronal activity via the Blood-Oxygen-Level-
Dependent (BOLD) contrast, which arises from localised changes in the ratio between 
oxygenated and deoxygenated haemoglobin owing to metabolic demands driven by neuronal 
activity (Ogawa et al., 1990; Logothetis et al., 2001). Functional MRI data can be acquired 
while participants engage in specifically designed paradigms, which generate activation and 
deactivation patterns pertaining to brain regions subserving language, executive functions, 
episodic memory and sensory-motor processing (Rao et al., 1993; Owen et al., 2005; Kim, 
2011; Price, 2012). In addition, “resting-state” fMRI sequences are commonly used, which 
specifically address spontaneous fluctuations of BOLD signal occurring during rest (i.e., task 
free conditions)(Fox and Raichle, 2007), and identify stable and reproducible sets of regions 
with strongly correlated signal time-courses, and high correspondence with task-implicated 
systems (Damoiseaux et al., 2006; Biswal et al., 2010).  
Ph-MRI studies have thus far been conducted mostly via task-based fMRI. Here, effects 
associated with pharmacological agents are predominantly shown as interaction effects, 
whereby a comparison takes place between activation patterns in subjects on drugs against 
placebo, or against subjects not taking the drug (Mehta and O'Daly, 2011). Randomised, 
double-blind, within-subject designs have also been implemented, though predominantly for 
assessments targeting psychiatric populations (Hafeman et al., 2012). The impact of drugs can 
be examined at a regional as well as at a network level, formalising connectivity properties via 
measures of statistical dependency between spatially separate BOLD time courses (Friston, 
2011). Compared to other in vivo techniques, including positron emission tomography (PET), 
the advantage of pharmacofMRI is to potentially assess large-scale systems providing 
snapshots of network architecture across multiple scales and during different tasks, irrespective 
of the pharmacodynamic properties of a given compound (Borsook et al., 2006; Nathan et al., 
2014). This resulted in pharmacofMRI to be used not only to investigate already marketed 
drugs, but also in the context of drug discovery (Nathan et al., 2014). 
This review summarises  pharmaco-fMRI studies of the most frequently prescribed AEDs. 
Where appropriate, analyses investigating the impact of AEDs on structural MRI metrics are 
also considered. (Hafeman et al., 2012). 
 
2.1 TOPIRAMATE AND ZONISAMIDE 
 
Topiramate (TPM) is currently approved for the treatment of epilepsy, in monotherapy as well 
as an add-on compound, and is additionally licensed for migraine prophylaxis (Bootsma et al., 
2004; Mula, 2012). Despite the efficacy of TPM across disease entities, there appears to be an 
association between its usage and neurocognitive impairment, both in healthy volunteers as 
well as patients with epilepsy and migraine disorders. Dysfunction appears to affect several 
domains, including sustained attention, psychomotor speed, working-memory, as well as 
expressive language skills, addressed by verbal fluency tasks (Martin et al., 1999; Thompson 
et al., 2000; Lee et al., 2003; Mula et al., 2003; Meador et al., 2005). 
The frequent incidence of cognitive impairment accompanying TPM treatment has prompted 
investigations into its pathophysiological underpinnings via cognitive functional MRI 
paradigms. TPM is the most frequently studied drug by pharmaco-fMRI, though in the majority 
with small participant samples (Beltramini et al., 2015; Wandschneider and Koepp, 2016). 
Given the impact on language skills, several studies utilised expressive language fMRI tasks, 
such as verbal fluency tasks, during which participants are usually required to generate words 
starting with specific letters (phonemic fluency). As these paradigms often alternate active with 
baseline blocks of low-demand information processing (e.g., cross-hair fixation), the activation 
maps generally reveal areas involved in speech production (dominant inferior frontal cortex) 
along with regions more broadly subserving attention, task execution and working memory, 
including dorso-lateral frontal, medial frontal and posterior parietal cortices. Implementing a 
verbal fluency task, Jansen and collaborators first revealed disrupted activation of inferior 
frontal and medial prefrontal cortices in five patients with focal epilepsy taking TPM against 
ten subjects with epilepsy not on TPM, along with variable reconfiguration of occipito-parietal 
activations (Jansen et al., 2006). Another verbal fluency study analysed ten patients on TPM 
for migraine prophylaxis, five of whom subjectively reported cognitive dysfunction. Compared 
with controls, attenuated activation of task-related frontal language areas was demonstrated in 
the subgroup with subjective cognitive difficulties, whereas subjects on TPM without cognitive 
deficits showed increased activation of language areas, interpreted by the authors as a potential 
compensatory mechanism (De Ciantis et al., 2008). A subsequent verbal fluency fMRI study 
on patients with epilepsy implemented a cross-sectional and a longitudinal component. For the 
cross-sectional arm, Yasuda et al. recruited patients with frontal lobe epilepsy (FLE) and 
demonstrated impaired task-related deactivation of midline fronto-parietal default mode areas, 
required for effective performance of cognitive tasks (Weissman et al., 2006; Sonuga-Barke 
and Castellanos, 2007), in patients on TPM compared to patients not taking TPM and healthy 
controls (Yasuda et al., 2013). This imaging trait interestingly displayed a highly significant 
positive correlation with drug dose. In the longitudinal component of the study, one TPM-off 
and one TPM-on task runs were compared for four FLE patients and two healthy volunteers, 
corroborating cross-sectional evidence of task-related failure to deactivate default mode areas 
during the TPM-on condition. In addition, qualitatively reduced activation of frontal language 
areas was also documented on TPM. Additional evidence of impaired deactivation of default 
mode areas during expressive language came from a subsequent study utilising a verb 
generation paradigm, asking participants to view concrete nouns and generate semantically-
correlated verbs (Tang et al., 2016). The investigators recruited a mixed group of 12 patients 
with focal epilepsy taking TPM as add-on therapy, six of whom subsequently discontinued it 
on clinical grounds. Overall, patients on TPM showed reduced task-related deactivation within 
anterior and posterior default mode areas compared with controls. In those who discontinued 
TPM, analysis of task-related maps post-withdrawal unveiled increased activation of right 
middle frontal and left superior occipital gyrus, as well as enhanced deactivation of left 
parahippocampal gyrus and bilateral posterior cingulate cortex.  
While the above detailed studies addressed expressive language, Szaflarski and collaborators 
implemented a semantic decision/tone decision fMRI task (Szaflarski and Allendorfer, 2012) 
to map the speech comprehension system, which extends to a considerable proportion of the 
prefrontal cortex, temporal areas (lateral and ventral, not reliably activated by verbal fluency 
tasks), as well as angular and posterior cingulate gyrus (Binder et al., 2008). Distinct activation 
patterns emerged when comparing left TLE patients on- versus off-TPM, and right TLE on- 
and off-TPM. Among patients with left-sided foci, those on TPM exhibited reduced activation 
of the left superior temporal gyrus and hyperactivation of the left anterior cingulate cortex 
compared with those off TPM. Right TLE patients on TPM presented with decreased activation 
of the inferior frontal gyrus and enhanced recruitment of bilateral superior frontal and left 
temporo-occipital areas. Further, greater prevalence of atypical language representation was 
noticed for both TLE patients on TPM than those off -TPM (Szaflarski and Allendorfer, 2012). 
In summary, fMRI studies addressing the impact of TPM on language networks utilised a 
variety of tests, examined different and heterogeneous subject categories, and generally relied 
on small sample sizes. Nonetheless, converging evidence across investigations points to 
disrupted activation of task-relevant fronto-temporal cortices, as well as impaired de-activation 
of task-negative regions, predominantly represented by the default mode network. The 
potential mechanisms leading to such effects have been speculated upon. The presence of a 
sulphonamide functional group provides TPM with carbonic anhydrase inhibition properties 
(Leniger et al., 2004), which may influence the regional BOLD contrast measured by fMRI. 
This was demonstrated for acetazolamide, a widely utilised carbon anhydrase inhibitor, shown 
to induce increases in cerebral perfusion while not affecting oxygen consumption (Bruhn et 
al., 1994). Thus, an altered ratio between rest and activation BOLD contrast may take place, 
represented by an attenuated signal change in response to an increase in activity of a certain 
area, as shown for the visual cortex during photic stimulation (Bruhn et al., 1994). While this 
phenomenon may prominently occur in brain areas recruited during a task, and might explain 
the attenuated activation of task-positive areas observed by fMRI studies, an elucidation of its 
influence on task-related deactivations and their spatial distribution appears less intuitive. 
Moreover, TPM is about 10 to 100 times less potent as carbon anhydrase inhibitor than 
acetazolamide (Shank et al., 1994) and exhibits multifaceted pharmacodynamic properties, 
including blockade of voltage-gated sodium channels, L-type calcium channels, 
AMPA/kainate subtypes of glutamate receptors as well as potentiation of GABAA-mediated 
neurotransmission (Perucca, 1997; Mula, 2012), whose effect on fMRI activation patterns also 
needs to be taken into account during data interpretation.  
Valuable insights may come from investigations addressing zonisamide, an AED utilised to 
treat focal and generalised epilepsies and associated with a profile of cognitive side effects 
which is comparable, though possibly more moderate, with that detailed for TPM (Ojemann et 
al., 2001; Mula and Trimble, 2009). Mechanisms of action of zonisamide include blockade of 
voltage-sensitive sodium channels, T-type calcium channels, modulation of dopaminergic and 
serotoninergic transmission as well as a neuroprotective effect from free-radical damage 
(Leppik, 2004; Patsalos, 2005). As described for TPM, zonisamide also exhibits a sulpha 
moiety and weak carbon anhydrase inhibition properties, estimated as 100-1000 times lower 
than acetazolamide (Leppik, 2004). A recent electroencephalography (EEG) study on 
individuals taking zonisamide for recent-onset epilepsy reported reduced current source 
density of beta frequencies for areas implicated in language and working memory, such as 
inferior and middle frontal cortices, anterior cingulate gyri and inferior parietal lobules (Kwon 
and Park, 2013). In a retrospective analysis of verbal fluency fMRI, comparing patients taking 
Topiramate (n=32), Zonisamide (51) and Levetiracetam (62) (Wandschneider et al., 2017), we 
observed a similar influence of zonisamide and TPM on fronto-parietal cognitive networks in 
patients with focal epilepsy, as measured by verbal fluency fMRI. However, impaired task-
related deactivation of default mode areas was described for the TPM group only, and not in 
individuals on zonisamide. These results provide evidence for medication-specific effects, 
substantially advancing our understanding of the impact of distinct AEDs on the architecture 
of cognitive networks. From a mechanistic viewpoint, it would remain to be established 
whether distinct effects of TPM and zonisamide may be ascribed to differences in carbonic 
anhydrase inhibition activity, which appears to be higher for topiramate. In this regard, 
characterising the influence of acetazolamide on cognitive performance and activation patterns 
during linguistic and executive tasks may prove useful. 
 
2.2 CARBAMAZEPINE/OXCARBAZEPINE 
 
Carbamazepine (CBZ) represents one of the first-generation AEDs and, along with its 
derivative oxcarbazepine (OXC), mainly owes its seizure suppressant activity to the inhibition 
of voltage-dependent sodium channels (Ambrosio et al., 2002). Interaction with potassium and 
L-type calcium channels, GABAA receptors as well as adenosine binding sites are also reported 
(Liu et al., 2006). CBZ represents the first drug to be investigated within an fMRI study setting. 
Jokeit and colleagues analysed a visuo-spatial memory retrieval task to activate mesiotemporal 
structures via mental navigation through a familiar route, in 21 individuals with drug-resistant 
TLE. An inverse correlation was detected between fMRI activations within mesiotemporal 
lobes and CBZ serum levels, with no additional influence exerted by lateralisation of epilepsy 
nor further contribution of CBZ-epoxide serum level to data explanation (Jokeit et al., 2001). 
This provides evidence for a CBZ-related attenuation of mesiotemporal activations with a 
linear dose-response relationship. More recently, a resting-state fMRI analysis on patients with 
TLE compared a subgroup treated with CBZ/OXC against participants taking other AEDs 
(Haneef et al., 2015), and characterised the organisational properties of functional networks 
via a graph-theoretical approach (Bullmore and Sporns, 2009). Patients treated with OXC/CBZ 
differed from those on other AEDs with respect to ‘betweenness centrality”, a metric utilised 
to identify ‘hubs’, nodes exhibiting high connectional weighs within the architecture of a 
network, and prominent roles in ensuring connectivity between distant brain areas. The authors 
detected variations of betweenness centrality in several nodes, including decreases in 
mesiotemporal and orbitofrontal areas, anterior cingulate cortices, angular gyrus, thalamus and 
putamen, co-existing with increases in posterior cingulate, insular, lateral temporal, posterior 
parietal and temporo-occipital cortices (Haneef et al., 2015). On balance, these results may 
indicate redistribution of hub properties with more marked shifts from limbic to lateral cortical 
areas in TLE treated with CBZ/OXC. Interestingly, recent evidence from graph theoretical 
analyses on structural and functional MRI datasets from patients with TLEpoints to disrupted 
nodal topology of limbic subnetworks (Liao et al., 2010; Chiang et al., 2014; Bernhardt et al., 
2015), along with major rearrangements of whole-brain network hubs, particularly involving 
para-limbic and lateral temporal cortices (Wang et al., 2014). Thus, CBZ/OXC may be 
influencing the topological properties of subnetworks specifically involved in disease 
pathomechanisms.  
 
2.3 LEVETIRACETAM 
 
Levetiracetam (LEV) is one of the most widely used AEDs, and received approval in numerous 
countries as monotherapy as well as add-on treatment for focal and generalised epilepsies. LEV 
binds to the synaptic vesicle protein SV2A, probably modulating synaptic neurotransmitter 
release (Lynch et al., 2004). In contrast to other AEDs, LEV has been repeatedly shown not to 
exert a detrimental impact on cognition, oror even amelioration of neuropsychological 
performance (Piazzini et al., 2006; Helmstaedter and Witt, 2008), depicting a more favourable 
profile than for other AEDs, including carbamazepine (Mecarelli et al., 2004; Meador et al., 
2007; Helmstaedter and Witt, 2010). A recent EEG study provided evidence for multi-domain 
cognitive improvement along with accelerated background frequencies in drug-naïve epilepsy 
patients after treatment with LEV (Cho et al., 2012).  
To characterise the imaging underpinnings of the effect of LEV on cognition, we utilised both 
a verbal and a visuo-spatial fMRI working memory task in a large cohort of 106 patients with 
TLE, 59 of whom treated with LEV, and with no between-group divergences regarding TPM 
or zonisamide co-medication. Compared with individuals not treated with LEV, patients on 
LEV exhibited increased task-related deactivations in the affected temporal lobe, namely in the 
left middle temporal gyrus in left TLE during the verbal working memory paradigm, and in the 
right hippocampus in right TLE during the visuo-spatial task. The latter effects occurred in a 
dose-dependent fashion, and were not evidenced when comparing patients treated with or 
without CBZ, or with and without lamotrigine (Wandschneider et al., 2014). Previous 
investigations characterising the functional architecture of working memory networks 
illustrated the association between attenuated activation of mesiotemporal structures and 
effective task performance (Dolcos and McCarthy, 2006; Cousijn et al., 2012). This may occur 
as part of a resource redistribution process from task-irrelevant to task-relevant regions, aiming 
to minimise interference (Anticevic et al., 2010; Cousijn et al., 2012). Interestingly, studies 
addressing the fMRI correlates of working memory in TLE detected failure to deactivate the 
hippocampus ipsilateral to the seizure focus compared with healthy controls (Stretton et al., 
2012), in the context of morpho-functional connectivity derangements pointing to a disrupted 
segregation between task-negative (mesiotemporal) and task-positive (parietal) areas (Stretton 
et al., 2013). Consequently, the influence of LEV on working memory networks in TLE, 
described by Wandschneider and colleagues, can be interpreted as a restoration of fMRI 
activation patterns described for healthy controls and, therefore, regarded as favourable. 
Further evidence of a normalising effect of LEV on mesiotemporal activation comes from 
functional imaging studies conducted on subjects with amnestic mild cognitive impairment 
(aMCI) (Bakker et al., 2015), in whom augmented task-related activations in mesiotemporal 
structures were documented during memory encoding tasks (Dickerson et al., 2004; Celone et 
al., 2006). Comparing a short treatment course with low-dose LEV versus placebo, Bakker and 
collaborators elegantly demonstrated a reversal of the aberrant activation patterns of dentate 
gyrus/CA3 hippocampal sub-regions and entorhinal cortex to levels normally observed in 
healthy controls, accompanied by a significant improvement in task performance (Bakker et 
al., 2012; Bakker et al., 2015).  
A recent analysis on patients with benign epilepsy with centro-temporal spikes (BCETS) 
documented an effect of LEV on the regional homogeneity (ReHo) of fMRI resting-state 
signal, which addresses the local synchronisation of fMRI time-series across a set of 
neighbouring voxels (Zang et al., 2004). As different from drug-naïve individuals, reduced 
ReHo was detected in patients on LEV in areas implicated in the generation of interictal 
epileptic spikes, such as fronto-centro-temporal cortices, basal ganglia and thalamus. 
Contrasting ReHo patterns in patients on LEV against those treated with sodium valproate 
(discussed below) revealed spatial specificity of drug effects, with LEV affecting more 
prominently fronto-temporal cortices and caudate nuclei while exerting a less pronounced 
influence on thalamic activity. LEV also exerted dissociating effects on the covariance of 
thalamic and centro-temporal local fMRI metrics, shown instead as significantly correlated in 
drug-naïve patients and subjects treated with valproate (Zhang et al., 2016). Unfortunately, the 
absence of a healthy control cohort in the above study impedes establishing whether regional 
homogeneity patterns in LEV-treated patients may indicate a reversal to normal baseline 
values.  
Collectively, evidence across different disorders suggests a disease-specific distribution of the 
effects of LEV, with predominant influence on subnetworks relevant to disease 
pathomechanisms. Its effects may further exhibit beneficial implications for cognitive 
performance, as demonstrated for conditions with impact on mesiotemporal function. 
 
2.4 SODIUM VALPROATE 
 
Sodium valproate (VPA) is a well-established broad-spectrum AED with efficacy to treat a 
multiplicity of focal and generalised epilepsy syndromes, is utilised as mood stabiliser for the 
treatment of bipolar disorder, and is also licenced for migraine prophylaxis (Perucca, 2002; 
Nalivaeva et al., 2009). VPA has long been regarded as a compound with diverse and complex 
mechanisms of action, which go beyond the potentiation of GABAergic neurotransmission and 
include attenuation of NMDA glutamate receptor activity, blockade of voltage-sensitive 
sodium channels, and modulation of dopaminergic and serotoninergic transmission (Loscher, 
2002; Perucca, 2002). Furthermore, VPA exposure leads to extensive modifications of gene 
expression, with downstream influence on transcription regulation, signal transduction and 
cellular homeostasis, probably underlain by its histone deacetylase (HDAC) pan-inhibition 
properties (Rosenberg, 2007; Nalivaeva et al., 2009; Rosenzweig et al., 2012). There is also 
evidence of potential neuroprotective effects brought about by VPA through the modulation of 
signalling cascades involved in neuronal apoptosis, formation of neurofibrillary tangles and 
amyloid plaques (Tariot et al., 2002). 
The effects of a two-week long VPA course on the activation patterns of spatial attention, 
working memory and verbal fluency tasks were recently addressed by an fMRI study on 
healthy volunteers. Analysing the magnitude of BOLD signal change pre- and post-
intervention across task-specific maps, Bell and collaborators observed attenuated activations 
for the spatial attention and word generation tasks in the VPA-treated cohort compared to 
subjects receiving placebo. ROI-based post-hoc analysis revealed changes to occur in the left 
lingual gyrus during the attention task, and to encompass the supplementary motor area for the 
verbal fluency task. On the other hand, individuals on two-week course of lithium presented 
with significantly reduced activations within working memory and verbal fluency maps, but 
not during the attention task (Bell et al., 2005). These findings may reflect a differential effect 
of VPA and lithium on cognitive fMRI activations, and point to the influence of VPA on 
expressive language and attention networks, with relative sparing of working memory. As 
neurobehavioral correlates were not provided, it remains undetermined whether such 
reconfigured patterns may be accompanied by performance changes. The above findings, 
however, may be in line with evidence from neuropsychological studies, collectively indicating 
a mild impact of VPA on measures of attention, psychomotor speed and executive functions 
(Thompson and Trimble, 1981; Meador et al., 2003; Mula and Trimble, 2009).  
Variable results were obtained in pharmaco-fMRI studies probing VPA-related effects in 
disease entities. In a small sample of children with mood dysregulation and familial history of 
bipolar disorder, no significant activation changes during an emotion attribution task were 
detected after three months of treatment with VPA, compared to baseline pre-treatment data. 
(Chang et al., 2009). Investigations on patients with epilepsy, on the other hand, may suggest 
beneficial effects of VPA on fMRI activation maps.  
Focusing on patients with juvenile myoclonic epilepsy (JME) and their un-affected siblings,  
we detected co-activation of motor and cognitive areas during a visuo-spatial working memory 
task in patients with JME and their siblings compared with controls, which may represent an 
imaging trait underlying the highly prevalent cognitively-triggered jerks (Wandschneider et 
al., 2012; Wolf et al., 2015; Koepp et al., 2016). In JME patients, we observed an inverse 
relationship between VPA dose and motor cortex activation, which is indicative of a 
“normalising effect” of VPA on the aberrant activation patterns documented for motor areas in 
JME (Vollmar et al., 2011). Structural and functional connectivity was augmented between 
motor areas and prefrontal cognitive networks (Vollmar et al., 2012), In line with the above, 
evidence of an influence of VPA on the excitability of the motor system was also provided by 
analyses implementing interleaved fMRI/transcranial magnetic stimulation (TMS). During 
classical stimulation of the motor hotspot, diffuse attenuation of TMS-correlated BOLD 
response was observed within several areas belonging to the motor system after a single dose 
of VPA compared with placebo (Li et al., 2010), along with reduction of effective connectivity 
between primary motor cortex and both premotor and supplementary motor areas (Li et al., 
2011). 
In subjects affected by BCETS, regional homogeneity of fMRI time courses was attenuated in 
regions demonstrated to be implicated in epileptic spike generation, including fronto-centro-
temporal cortices as well as thalamus, in subjects treated with VPA compared with drug-naïve 
individuals. Attenuation of centro-temporal regional homogeneity also appeared dose-
dependent. Compared with LEV, the impact of VPA was more pronounced on thalamic activity 
and less evident for cortical regions. Further, subjects on VPA displayed preserved covariance 
of fMRI metrics between thalamus and centro-temporal cortices, possibly suggesting a 
balanced effect on both cortical and subcortical structures associated with VPA (Zhang et al., 
2016).  
Imaging correlates of VPA use have also been sought for by structural MRI studies, possibly 
following early case reports of reversible VPA-associated pseudoatrophy and neurobehavioral 
deterioration (Papazian et al., 1995; Guerrini et al., 1998). In small samples of young 
individuals with subsyndromal bipolar disorder and matched controls, Chang and colleagues 
described no evidence of changes in total brain or amygdala volume after a three-month course 
of VPA (Chang et al., 2009). Moreover, VPA-treated adult patients with bipolar disorder were 
shown to present with greater volumes of anterior and posterior cingulate cortices, which 
exhibited a trend-level negative correlation with symptom severity (Atmaca et al., 2007). On 
the other hand, recent longitudinal clinical trials evaluating the effectiveness of VPA for the 
treatment of agitation and psychosis in Alzheimer’s disease observed accelerated rates of 
whole-brain and hippocampal volume loss, along with more rapid ventricular expansion 
compared to the placebo cohort (Fleisher et al., 2011; Tariot et al., 2011). These changes were 
also paralleled by faster cognitive decline over the first treatment year, as measured by the 
Mini-Mental State Examination (Fleisher et al., 2011). In young children (age 6-8) incurred in 
prenatal exposure to VPA, an analysis revealed augmented cortical thickness of the pars 
opercularis of the left inferior frontal gyrus and of the left medial occipital cortex, with loss of 
the expected right-to-left thickness asymmetry within inferior frontal cortices. Further, a trend 
towards a negative correlation was observed between left fronto-opercular thickness and a 
composite measure of verbal comprehension (Wood et al., 2014). This study provides an 
imaging correlate of neurobehavioral findings detailed by multiple investigations, linking in 
utero exposure to VPA with poorer cognitive outcomes across several domains, particularly 
verbal abilities (Adab et al., 2004; Gaily et al., 2004; Meador et al., 2009; Meador et al., 2013), 
along with increased likelihood of atypical language lateralisation (Meador et al., 2011; 
Nadebaum et al., 2011). A study by Pardoe and colleagues identifiedreductions in total whole 
brain volume, white matter volume as well as parietal lobe thickness in subjects treated with 
VPA compared with healthy controls and patients not on VPA. These findings were 
documented in two separate cohorts, one represented by subjects with drug-resistant focal 
epilepsy and another consisting of patients with childhood-onset seizures. Effects associated 
with VPA were thought to be reversible, as no differences could be detected between previous 
VPA users and patients who were never prescribed the drug (Pardoe et al., 2013). The 
biological meaning of reductions in parietal lobe thickness could not be inferred, owing to the 
clinical heterogeneity of the analysed subjects, the absence of direct correlations with cognitive 
measures and of details regarding potential differences in seizure control among patient groups. 
Regarding decreases in white matter volume, however, experimental and human studies point 
to an impact of VPA on late-differentiating oligodendrocytes, due to its action as histone 
deacetylase pan-inhibitor (Shen et al., 2008; Rosenzweig et al., 2012). This effect may 
influence myelination/re-myelination efficiency, leading to derangements in white matter 
architecture and particularly affecting later-myelinating plastic circuits, which play crucial 
roles in multi-modal associative processing, cognitive control and goal-directed behaviour 
(Rosenzweig et al., 2012). 
On balance, recent investigations have considerably advanced our understanding of the 
functional and structural MRI correlates of VPA usage. Overall, results of the above detailed 
studies appear multifaceted. While some fMRI studies may suggest a beneficial influence of 
VPA, with reverberation on disease-specific subnetworks, morphometry analyses concordantly 
report detrimental effects correlated with VPA use across diverse conditions, each of which 
tapping into different life spans. Proved heterogeneity in the analysed cohorts, study design 
and confounding factors may be accounted for the wide spectrum of findings. It is also possible, 
however, that the pleiotropic pharmacodynamic of VPA might lead to unique phenotypes 
arising from specific interactions between disease- and drug-related effects, ultimately 
justifying marked variability of imaging features condition per condition. 
 
2.5 LAMOTRIGINE  
 
Lamotrigine (LTG) is a drug with broad spectrum efficacy, spanning from focal to generalised 
epilepsy syndromes and including bipolar disorder, owing to its mood stabilisation properties. 
Its principal mechanism of action is represented by the use- and voltage-dependent blockade 
of sodium channels (Cheung et al., 1992; Coulter, 1997), possibly accompanied by inhibition 
of voltage-sensitive calcium currents, anti-glutamatergic and neuroprotective effects (Ketter et 
al., 2003).  
Though a variety of research groups set out to investigate LTG-associated functional imaging 
markers, no studies at present recruited patients with epilepsy. Li and collaborators carried out 
a series of investigations aiming to establish the influence of LTG on fMRI activation patterns 
during motor and prefrontal TMS in healthy volunteers. As previously detailed for VPA, LTG 
was also shown to diffusely attenuate TMS-induced BOLD response over several areas of the 
motor system (Li et al., 2004; Li et al., 2010), and to impact effective connectivity between 
primary motor cortex and both premotor and supplementary motor areas (Li et al., 2011) 
compared with placebo. LTG-specific effects, however, emerged during prefrontal TMS, 
which generally elicits the activation of medial prefrontal as well as primary sensory areas. 
TMS-correlated fMRI activations for the LTG condition encompassed broader areas, with 
significantly increased recruitment of ipsilateral hippocampus, medial frontal, anterior 
cingulate and orbitofrontal cortices compared to placebo (Li et al., 2004; Li et al., 2010). This 
pattern was not detected for VPA, which caused attenuated activation of all target regions of 
prefrontal TMS when compared against placebo, and also of the above mentioned limbic areas, 
when directly compared with LTG (Li et al., 2010). Moreover, LTG was associated with 
increases in TMS-correlated effective connectivity between ipsilateral dorsolateral prefrontal 
and anterior cingulate cortex, while the same findings could not be detailed for VPA (Li et al., 
2011). As limbic hyperactivation, frontal hypoactivation and dysfunctional fronto-cingulate 
connectivity have been implicated in the pathophysiology of major depression and bipolar 
disorder (Schlosser et al., 2008; Sheline et al., 2010; Kupferschmidt and Zakzanis, 2011; 
Pizzagalli, 2011; Strakowski et al., 2012), these findings provide support to the view that LTG 
may influence activity and connectional properties of brain areas relevant to disease 
pathophysiology. Indeed, several analyses focused on verbal working memory and facial 
emotion recognition fMRI in individuals with bipolar disorders. Haldane and colleagues report 
increased recruitment of task-relevant areas, such as dorso-lateral prefrontal, medial frontal and 
anterior cingulate cortices, after a six-week course of LTG (Haldane et al., 2008). In paediatric 
patients, reduced activation of the right amygdala during negative facial emotion recognition 
was detected after 8 weeks of treatment with LTG, and was positively related to improvements 
in depressive symptoms (Chang et al., 2008). Additional evidence of attenuated temporal 
activations during emotion recognition was documented for adults after 12 weeks of LTG 
monotherapy (Jogia et al., 2008). Once again in subjects with bipolar disorder, Pavluri and 
colleagues detailed augmented activation of lateral temporal, medial frontal, left inferior and 
middle frontal cortices during a response inhibition task after 14 weeks of initial anti-psychotic 
treatment followed by LTG monotherapy. These findings corresponded to a normalisation of 
task-related activations, which correlated with symptom amelioration (Pavuluri et al., 2010).  
There is also evidence that LTG may contribute to revert the fMRI correlates associated with 
ketamine, a well-known antagonist of NMDA glutamate receptors. After administration of 
ketamine, an investigation reported reduced activation of orbitofrontal and sub-genual 
cingulate cortices and hyperactivation of posterior cingulate, lateral temporal cortices and 
thalamus. Interestingly, pre-treatment with LTG led to the suppression of several of the former 
changes (Deakin et al., 2008). 
In summary, several investigations conducted on adolescent and adult patients with mood 
disorders documented the effect of LTG on disease-relevant regions, largely part of fronto-
limbic circuits involved in the regulation of emotional responses and/or implicated in response 
inhibition and task execution. Collectively, such influence was shown to contribute to the 
restoration of activation patterns described for healthy controls, and hence can be defined as 
“normalising”. 
 
2.6 GABAPENTIN AND PREGABALIN 
 
Both gabapentin (GBP) and pregabalin (PGB) selectively bind to the α2δ subunit of voltage-
gated calcium channels, leading to enhanced GABA-mediated inhibition and diminished 
release of neurotransmitters such as glutamate, serotonin, noradrenaline and substance P (Gee 
et al., 1996; Fink et al., 2002; Dooley et al., 2007). Their clinical indications are particularly 
broad, ranging from the treatment of focal epilepsy syndromes to neuropathic pain conditions 
for both compounds, and encompassing generalized anxiety disorder for PGB only (Feltner et 
al., 2003; Gilron et al., 2005; French et al., 2016). At present, no studies have been conducted 
to image the action of GBP or PGB in patients with epilepsy. A small number of functional 
imaging studies, however, addressed the effects of these two drugs in healthy volunteers, 
investigating brain activity related to pain processing, emotional anticipation and response to 
emotional faces. With a pharmacological fMRI study design, Iannetti and colleagues elucidated 
the modulatory effects of a single GBP dose on brain activation during nociceptive mechanical 
stimulation and experimentally-induced secondary hyperalgesia, the latter being a proxy for 
central sensitization. Although no significant changes were evidenced by pain/hyperalgesia-
related ratings, GBP-correlated imaging features included attenuated activation of operculo-
insular cortices in both conditions. During central sensitization, reduced activations were 
additionally noticed in the brainstem, along with a reduction of stimulus-correlated 
deactivations during central sensitization only (Iannetti et al., 2005). These findings provided 
quantitative traits for GBP-correlated effects, suggesting its specific influence on well-
established pain-processing regions, particularly in the context of central sensitisation. After 
acute administration of PGB to healthy volunteers, an fMRI paradigm addressing the 
anticipation responses to positive and negative emotional images reported decreased activation 
of left amygdala and anterior insula as well as hyperactivation of the anterior cingulate cortex 
compared with placebo (Aupperle et al., 2011). Moreover, an analysis of emotional face 
processing in the same study cohort revealed attenuated activation of the left amygdala in 
relation to fearful face processing, of the left insula specifically for angry faces, and of the 
fusiform gyrus for stimulus types (Aupperle et al., 2012). Interestingly, reduction of amygdalar 
activation was also reported in other functional imaging studies addressing the influence of 
benzodiazepines (Paulus et al., 2005) and selective serotonin reuptake inhibitors during 
emotional face processing (Arce et al., 2008; Windischberger et al., 2010), while the insula has 
long been regarded as a key hub for interoception and elaboration of emotional responses 
(Craig, 2009; Singer et al., 2009). In this context, PGB may be exhibit a similar neural target 
to other compounds with anxiolytic properties, and exert its effects through a modulation of 
the activity of limbic and para-limbic circuits with salient roles in regulating responses to 
emotional stimuli.  
 
3. INSIGHTS FROM MAGNETIC RESONANCE SPECTROSCOPY 
 
Proton magnetic resonance spectroscopy (1H-MRS) represents a non-invasive technique with 
the ability to provide quantitative measurements of specific chemical entities in determined 
volumes of interest. Owing to shifts in resonance frequencies induced by the local proton 
environment (referring to atoms within and surrounding a given molecule), 1H-MRS produces 
a spectrum with several peaks at distinct frequencies, each one specific to a given molecular 
compound, and whereby the area underlying each peak relates to the concentration of the 
corresponding molecule (De Graaf, 2013). AEDs are presumed to exert their seizure 
suppression activity either via potentiating inhibition mechanisms or via an attenuation of 
excitatory neurotransmission (Rogawski and Loscher, 2004), and this represented the 
underlying rationale of several investigations aiming to determine concentrations of GABA 
and glutamate (often indistinguishable from glutamine, resulting in a “Glx” composite metric) 
in patients with epilepsy, and to correlate the former with treatment administration as well as 
clinical response (Petroff et al., 2000; Mueller et al., 2001; Mueller et al., 2003; Simister et al., 
2009). This topic has been elegantly reviewed by Van Veenendaal and collaborators (van 
Veenendaal et al., 2015), who highlighted the potential of MRS to provide biomarkers 
predicting AED-related treatment outcomes, and to shed light into the mechanistic 
underpinnings of treatment failures and cognitive side effects.  
AEDs with direct impact on GABAergic neurotransmission represent by far the most 
frequently investigated by MRS studies. There is a considerable body of evidence indicating 
enhanced GABA concentrations after acute and chronic administration of vigabatrin (VGB) 
(Petroff et al., 1996b; Novotny et al., 1999; Petroff et al., 1999; Weber et al., 1999; Mueller et 
al., 2001; Mueller et al., 2003), an irreversible inhibitor of GABA transaminase, GBP (Petroff 
et al., 1996c; Kuzniecky et al., 2002; Cai et al., 2012), which increases GABA availability via 
the modulation of voltage-dependent calcium channels, and TPM (Petroff et al., 2001; 
Kuzniecky et al., 2002), which potentiates GABAA-mediated neurotransmission. After 
treatment initiation with both VGB and GBP, GABA concentrations were shown to correlate 
with seizure reduction in patients with focal epilepsy (Petroff et al., 1996a; Petroff et al., 
1996c). Moreover, VGB doses were shown to correlate linearly with GABA concentrations 
until dosages of 3g/die, exhibiting a plateau for additional dose increases (Petroff et al., 1996d). 
Mueller and collaborators sought for MRS biomarkers of treatment response in subjects 
exposed to VGB, and emphasized the relevance of low pre-VGB GABA levels, followed by 
sharper increases of the latter after treatment start, as a potential response-associated trait in 
individuals with refractory focal epilepsy (Mueller et al., 2001). Moreover, the difference in 
GABA concentrations between the epileptogenic and non-epileptogenic hemisphere before 
VGB treatment was demonstrated to relate to improved seizure control under VGB therapy, 
regardless of the proximity of data sampling to the epileptogenic focus (Mueller et al., 2003). 
The above findings are collectively indicative of meaningful correlations between AED 
administration, modulation of GABA concentrations and clinical improvements. However, 
such level of detail is available for VGB only, which has unfortunately incurred in marked 
usage restrictions owing to the risk of potentially irreversible peripheral visual field deficits 
(Lawden et al., 1999). Exposure-response relationships have not been documented for TPM 
and GBP, despite evidence of increased GABA concentrations associated with these AEDs. In 
addition, a study investigating the effects of tiagabine, an AED with GABA reuptake inhibition 
properties, detected no influence on GABA levels after a single-dose administration (Myers et 
al., 2014), suggesting of complex and potentially marked compound-specific relationships 
between drug administration and neurotransmitter effects. 
Other MRS studies analysed GABA concentrations associated with AEDs not exhibiting a 
clearly documented influence on GABAergic neurotransmission. As for LTG, GABA 
concentrations were not elevated after acute administration nor after 2 weeks of LTG 
administration, but were shown as enhanced after 4 weeks (Kuzniecky et al., 2002). Similar 
results were obtained for LEV. A study on healthy volunteers reported no effects on GABA 
concentrations after three and six hours following a single dose of LEV (Kuzniecky et al., 
2008), but subsequent evidence of increased GABA levels 2-6 weeks after initiation of LEV 
therapy was gathered for the responder subgroup of patients with focal epilepsy (Doelken et 
al., 2010). Overall, these findings may suggest that augmented GABAergic neurotransmission 
be an indirect effect associated with chronic administration of AEDs with non-GABAergic 
mechanisms of action, and might correlate with response to treatment. 
In contrast with the abundance of evidence on GABA levels, there are fewer reports on AED-
correlated effects on glutamate/glutamine concentrations. Single doses of GBP administered 
to healthy subjects did not produce measurable glutamate changes (Cai et al., 2012; Preuss et 
al., 2013), and no modifications of Glx concentrations were detected by a longitudinal study 
assessing patients with epilepsy treated with VPA (Simister et al., 2007). On the other hand, a 
study analysing the effects of acute TPM administration in healthy controls, and separately 
modelling glutamate and glutamine, detected increased glutamine within a sampling voxel 
located in the anterior cingulate cortex, but no modifications of occipital glutamine and no 
variations in both anterior cingulate and occipital glutamate (Moore et al., 2006). On balance, 
no comprehensive inferences can be drawn regarding the influence of various AEDs on 
excitatory neurotransmission, arguably due to variability in study design and lack of 
longitudinal assessments.  
Other metabolites measured via 1H-MRS include N-acetylaspartate (NAA), a widely accepted 
marker of neuronal integrity (Rigotti et al., 2007), as well as myoinositol, which is a glial 
marker exhibiting a critical role in the regulation of osmotic balance and, as a precursor of 
membrane phospholipids and phosphoinositides, is required for cell membrane and myelin 
integrity (Brand et al., 1993; Haris et al., 2011). In patients with TLE, assessed after one to two 
years from initiation of AED therapy, lower NAA concentrations within the ipsi- and 
contralateral mesiotemporal sampling voxel were detected in those failing to respond to their 
first AED compared with those reporting seizure freedom (Campos et al., 2010). These 
findings may represent a biomarker of AED response, potentially indicating higher levels of 
neuronal damage in subjects with less favourable profiles of drug-responsiveness. As various 
AEDs were implicated, however, compound-specific effects could not be established. In a 
longitudinal study on a mixed epilepsy cohort, mostly represented by idiopathic generalised 
epilepsy, Simister and colleagues detected reduced myoinositol levels for subjects scanned 
while on VPA compared with the non-VPA condition, whereas no changes were observed for 
other metabolites, including Glx and NAA. No correlations were identified between 
myoinositol levels and seizure frequency or VPA dosage (Simister et al., 2007). Lower 
concentration of myoinositol was also detected in IGE patients treated with VPA compared 
with those not taking VPA (Simister et al., 2003). It is tempting to speculate whether altered 
myoinositol levels associated with VPA exposure may be related to its putative influence on 
myelination efficiency (Rosenzweig et al., 2012). Animal studies, however, suggest similar 
effects associated with lithium (O'Donnell et al., 2000), and further research in humans is 
advocated to establish whether reduction of myoinositol may also occur in association with 
other AEDs. 
With respect to MRS signatures of AED-related cognitive side effects, Van Veenendaal and 
colleagues recently conducted a cross-sectional study to address the relationship between 
processing speed and neurotransmitter levels in patient with focal epilepsy receiving AED 
therapy (van Veenendaal et al., 2016). Across all participants, glutamate concentrations were 
positively related to processing speed. In individuals taking TPM, deemed as ‘high-risk’ for 
cognitive dysfunction, lower glutamate levels and lower processing speed scores were detected 
compared with patients under LEV and LTG (‘low-risk’ category). Lower glutamate levels but 
no differences in processing speed, on the other hand, were observed in the ‘intermediate risk’ 
category, grouping VPA, CBZ/OXC and phenytoin, compared to low-risk individuals. Thus, 
these finding may suggest a potential contribution of AED-associated lower glutamate levels 
to suboptimal cognitive functioning in patients with epilepsy. However, no correlations were 
found between GABA levels, cognitive performance and AED-associated risk category. 
Occipital data sampling might have partially obscured GABA-related effects, in view of 
previous evidence linking GABA concentrations with motor decision speed in prefrontal, but 
not occipital areas (Sumner et al., 2010).  
In summary, studies implementing MRS rely on a variety of markers addressing 
complementary features of brain function, have remarkably shed light on the molecular 
underpinnings of AED effects, and might provide useful indicators to monitor treatment 
response and associated side effects. 
 
 
4. CONCLUSION 
 
Collectively, this review of pharmcao-fMRI and MRS studies strongly supports the potential 
of imaging investigations to provide MRI biomarkers of AED-correlated effects, which can be 
characterised within regions and networks implicated in disease pathomechanisms. 
The observed effects may not always specific to a given AED in an individual disease entity, 
given the considerable variability in participant inclusion criteria, study design andspecifics of 
the implemented paradigms,. A series of highly meaningful patterns however emerge, 
suggesting the influence of some AEDs on brain targets implicated in disease pathophysiology, 
or potentially involved in the emergence of drug-related adverse effects: 
 TPM has been mostly investigated due to its adverse impact on expressive language 
and executive functions, and cognitive fMRI studies overall revealed its negative 
influence on the activation of language areas, accompanied by attenuations of task-
correlated deactivations.  
 CBZ attenuated activation of mesiotemporal activations with a linear dose-response 
relationship 
 LEV favourably influenced the activity in dysfunctional mesiotemporal areas both in 
TLE and mild cognitive impairment, overall leading to a restoration of normal function.  
 VPA’s widely variable and often diverging effects warrant further multi-modal MRI 
analyses on well-characterised cohorts of patients and control subjects, which may 
allow to better disentangle anatomo-functional trajectories correlated with its usage. 
 LTG seems instead to be primarily exerting an effect on fronto-temporo-limbic 
circuitry involved in the regulation of emotional responses.  
 GBP and PGB have been shown to affect areas with prominent roles in nociception and 
emotion regulation, respectively, in line with their clinical indications.  
  
It remains to be shown to which extent drugs with distinct pharmacodynamic properties may 
ultimately influence common final pathways, giving rise to overlapping MRI correlates. This 
may be the case, for instance, of PGB and other compounds exhibiting anxiolytic properties, 
such as benzodiazepines and selective serotonin reuptake inhibitors (Aupperle et al., 2011; 
Aupperle et al., 2012). Further studies are required to understand whether this might also occur 
for different AEDs in people with epilepsy. A further complicating factor is represented by the 
intrinsic features of the BOLD contrast utilised in fMRI, which offers an indirect measure of 
neural activity. As shown for TPM and ZNS, a compound can concurrently exert an influence 
on both the neuronal and vascular compartments, potentially confounding any mechanistic 
interpretation of the fMRI correlates of pharmacological interventions. Strategies to 
disentangle vascular from neuronal effects include the implementation of perfusion MRI 
sequences such as arterial spin labelling (Borsook et al., 2013), which has been already pursued 
in some of the above discussed analyses (Aupperle et al., 2011; Aupperle et al., 2012).  
While most MRI studies discussed above have either enrolled healthy volunteers, or sought to 
establish functional markers of drug effects on cognitive networks in patient populations, there 
is relative scarcity of MRI investigations aiming to establish imaging correlates of drug 
response, such as seizure-freedom for epilepsy. The latter issue may be more thoroughly 
addressed via longitudinal imaging studies comparing responders with non-responders and 
recruiting patients at different time points of their disease course. In this context, multi-modal 
complementary approaches may undoubtedly represent an asset. As discussed in the previous 
paragraph, an excellent example is represented by the added value of MRS, which has 
repeatedly proven useful in establishing the neurochemical underpinnings of the 
administrations of numerous AEDs, with some reports of correlations between clinical 
variables and neurotransmitter quantifications. As for any modality, MRS also suffers from 
limitations, mostly pertaining to data sampling, which is limited to large regions of interest, 
oftentimes in the occipital lobes only, and does not currently allow distinguishing synaptic 
from extra-synaptic neurotransmitter pools (Duncan et al., 2014; van Veenendaal et al., 2015). 
Further insights may come from investigating both imaging and neurophysiological techniques 
simultaneously, including EEG, TMS, or TMS-EEG, which offer complementary windows 
into the complex patterns of brain function and have demonstrated considerable potential to 
provide biomarkers of AED effects (Badawy et al., 2010; Cho et al., 2012; Badawy et al., 
2014; Ziemann et al., 2015; Premoli et al., 2016). 
Lastly, the identification of biomarkers associated with pharmacological interventions has 
gained considerable attention in the context of personalised medicine, whereby inferences 
pertaining to drug effects should be drawn to tailor clinical decisions to the individual patient. 
All studies in this review, however, detailed findings obtained at the group level. Whether the 
above discussed AED-related effects may be utilised for individually customised clinical 
decision making remains to be shown. To this end, remarkable advancements may be brought 
about by initiatives aiming to develop personalised brain network models, such as the “Virtual 
Epileptic Patient” recently proposed by Jirsa and collaborators (Jirsa et al., 2017). 
In conclusion, MRI studies have improved our understanding of the impact of AEDs on single 
regions and complex brain networks, and provide biomarkers of clinical relevance, with 
encouraging prospects for improving the clinical management of epilepsy. 
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